Best Stocks to Trade

(S) - Sprint Revenue Declined 10 Percent to $8.1 Billion

2009-07-29T09:29:00.000-07:00

Quotation of the Day:
“It takes a while for perception to catch up with reality,” Mr. Hesse said. “There are no quick fixes.”

Full-text:
http://www.nytimes.com/2009/07/30/technology/companies/30sprint.html?hpw=&pagewanted=print

How Flash Orders Work

2009-07-27T09:09:00.000-07:00

It’s basically like the scam from Office Space. Stealing a few pennies at a time, millions of times a day. Who’s gonna notice? Full-text: http://seekingalpha.com/article/151385-how-flash-orders-work

Restanza(TM) Shows 100% Survival - ADLS

2009-07-26T15:26:00.000-07:00

Press Release

Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study

CHICAGO, June 23 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced that a second non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin), showed that a 14-day course of Restanza achieved a 100% survival rate against an inhaled lethal dose of anthrax. All of the animals in the study that received 16 mg/kg once-a-day (the human equivalent dose of 300 mg) of Restanza within 24 hours after exposure to anthrax survived while none of the animals that received placebo survived. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), which is a component of the Department of Health and Human Services (HHS), an agency of the U.S. Government.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

"The successful outcome of the study provides strong evidence of Restanza's life saving potential and underscores its value as a potent new biodefense countermeasure," said Dr. Michael Flavin, Chairman and CEO of Advanced Life Sciences. "When coupled with the positive outcome of the pivotal primate study that we announced in May 2007, we believe that these significant findings complete the regulatory package for Restanza in the post-exposure prophylactic treatment of inhalation anthrax indication. We are looking forward to working with NIAID on the final study report and submitting our data package for regulatory review based on our NDA for Restanza, which is currently under review by the FDA for the treatment of mild-to-moderate community acquired pneumonia (CAP)."

Restanza as a Biodefense Countermeasure

Advanced Life Sciences is developing Restanza for the post-exposure prophylactic treatment of inhalation anthrax to help protect against human infection from anthrax. In studies conducted by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Restanza was shown to be highly active in vitro against 30 strains of anthrax. In May 2007, a non-human primate study showed that a 30-day course of oral Restanza was 100% protective against a lethal dose of inhaled anthrax as compared to the standard of care, Cipro(R) (ciprofloxacin), which demonstrated 90% protection. The FDA has designated Restanza as an orphan drug for the post-exposure prophylactic treatment of inhalation anthrax, but the FDA has not yet approved the drug for marketing in this or any other indication.

In addition to its development in anthrax, Restanza is also being developed to combat other high priority bioterror agents such as Fransicella tularensis (tularemia), Yersinia pestis (plague) and Burkholderia pseudomallei (melioidosis) under a two year, $3.8 million contract with the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense.

FDA's "Animal Efficacy Rule" and the Use of Non-Human Primates

The "Animal Efficacy Rule" allows for approval of new drug products based on animal data when adequate and well-controlled efficacy studies in humans cannot be ethically conducted because the studies would involve administering a potentially lethal or permanently disabling toxic substance or organism to healthy human volunteers. Approval of a drug under the "Animal Efficacy Rule" is subject to certain post-approval commitments, including the submission of a plan for conducting post-marketing studies, post-marketing restrictions to ensure safe use (if deemed necessary), and product labeling information intended for patient advising that, among other things, indicates the product's approval was based on efficacy studies conducted in animals alone.

The non-human primates used in the study referenced above were used to help understand anthrax disease mechanisms and to assess novel approaches for the prophylactic treatment of inhalation anthrax in lieu of human efficacy testing pursuant to FDA's "Animal Efficacy Rule" (21 C.F.R. Section 314.600-650). The study referenced above was carried out in accordance with the Animal Welfare Act (AWA) under the supervision of an Institutional Animal Care and Use Committee (IACUC), which is responsible for enforcing the AWA.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. For more information, please visit us on the web at www.advancedlifesciences.com

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

SOURCE Advanced Life Sciences Holdings, Inc.

CONTACT: Joe Camp of Advanced Life Sciences, +1-630-754-4352, jcamp@advancedlifesciences.com

First rule of trading: Don't loose your dough.

2009-07-25T09:57:00.000-07:00

"Remember, it's not what you own, any fool can go out and buy any stock. It's where you own it from, so wait and get the right entry."
--Dan Fitzpatrick, Source: video: http://www.thestreet.com/video/10552279/top-5-natural-gas-stocks.html#30574093001

First rule of trading: "Don't loose your dough."

5 Natural Gas Stocks - APA, STO, UNG, CHK, APA, APC

2009-07-25T09:44:00.000-07:00

5 Natural Gas Stocks that Should Skyrocket in 2009
July 25, 2009, summary by K.A.W.

UNG is the biggest ETF in natural gas.
Oil has had volitility.
Will see similary action in natural gas.
Dan Dicker is big bull on natural gas.
60% rise by December.
APA, STO, UNG, CHK, APA, APC.
Buy, buy, buy.

Source video: http://www.thestreet.com/video/10552279/top-5-natural-gas-stocks.html#30580802001

Options Trading: How to leverage market volatility into profits

2009-07-22T18:57:00.000-07:00

When trading options, the key to winning speculation is to risk as little money as possible to make the biggest return. And that perfectly describes the opportunity Iâ€™ll be presenting you today.

For starters, let’s look at the stock movements of some of the top mortgage lenders. On July 10th 2007, Fannie Mae (FNM â€“ NYSE) closed at $66.49. Today it trades for $34.34, good for a 50% loss.
Full-text: Options Trading: How to leverage market volatility into profits

SNDK - SanDisk's Memory Returns, Swings to Profit

2009-07-22T18:35:00.000-07:00

Posting a profit was once a distant memory for SanDisk(SNDK Quote), but no longer. The maker of flash-memory cards swung to profit in the second-quarter, bolstered by increased prices, higher royalty revenue and strong execution.
Full-text: SanDisk Remembers How to Make Profit

Market Updates: Apple (AAPL), Coca Cola (KO), CIT Group (CIT), BlackRock (BLK)

2009-07-22T06:45:00.000-07:00

iPhones Carry Apple (AAPL 151.51 ↑0.00%) Past Wall Street Estimates; Coca-Cola Beats Estimates of Overseas Sales; CIT (0.87 ↓11.22%) May Still Face Bankruptcy; TARP Czar Calls for Transparency; Caterpillar (CAT 38.89 ↓1.45%) Stock Jumps on Brighter Outlook; BlackRock (BLK 182.72 ↓0.77%) Beats Estimates, State Street Falls Short; Merck Considering Partner For Schering-Plough Consumer Health Operations; Yahoo Sales Down, Profit Up

Full-text: Market Updates: Apple (AAPL), Coca Cola (KO), CIT Group (CIT), BlackRock (BLK)

The 10 Commandments of Investing

2009-07-21T06:11:00.000-07:00

Use these rules to guide you on the road to financial freedom.

The biblical Ten Commandments were intended to act as a driver's manual for the road of life. "Thou shalt not kill." "Thou shalt not lie." These are life's version of the stop-at-the-red-light-and-advance-when-safe rules of the road. In other words, they are all guidelines to keep people out of trouble. Because life's highways are full of potholes, blind turns and bad drivers, the investing world also suffers from scandals, scams and dishonest companies. Here are 10 commandments for the investing world designed to help keep investors - and their money - safe:

1. Thou shalt set clear goals.
2. Thou shalt put thy financial house in order.
3. Thou shalt question authority.
4. Thou shalt not follow sheep.
5. Thou shalt be humble.
More...

Full-text: The 10 Commandments Of Investing

Knowing the Future

2009-07-19T17:09:00.000-07:00

Power Quotation:

"The reality is that what an investor "knows" about the future is small compared to what he can't know."
--Just One Thing, pg.31

A Guru's Guide to Winning Trades

2009-07-18T09:24:00.000-07:00

Dennis Gartman's Simple Rules Of Trading

1. Never, Ever, Ever, Under Any Circumstance, Add to a Losing Position... not ever, not never! Adding to losing positions is trading's carcinogen; it is trading's driving while intoxicated. It will lead to ruin. Count on it!

2. Trade Like a Wizened Mercenary Soldier: We must fight on the winning side, not on the side we may believe to be correct economically.

3. Mental Capital Trumps Real Capital: Capital comes in two types, mental and real, and the former is far more valuable than the latter. Holding losing positions costs measurable real capital, but it costs immeasurable mental capital.
Full-text: http://www.wealthdaily.com/articles/dennis-gartman-letter/1673

Information is sunshine - Signposts in the Fog - Andy Kessler

2009-07-18T08:43:00.000-07:00

Do they get stock ideas from all this stuff? I highly doubt it. The fire hose of information is for one reason and one reason only -- to take the pulse of the market and figure out what everyone else already knows. Information is sunshine. I want to know everything, because then and only then can I know if my investment ideas are already out there -- or are they still just figments of my twisted mind, outlines in the fog, flutters in my gut.
--Andy Kessler, Just One Thing.

4 Strategies for Managing Trader Stress - Summary

2009-07-17T09:28:00.000-07:00

Summary:

Fact #1: The human body doesn't care if it's a BIG stress or a little one.
Fact #2: Understanding basic physiology brings new awareness you can use to reduce stress.
Fact #3: Choosing the right hormones maximizes performance.
Fact #4: Your brain and heart work best when there is synchronization between all systems. This is called coherence.
Emotional Management Maximizes Traders' Health and Performance
Becoming coherent by shifting the emotion you're in creates an attitude shift, resulting in greater perceptual and mental clarity. Great athletes do it all the time (think Tiger Woods).

Full-text: 4 Strategies for Managing Trader Stress

Want to Become a Winning Trader? Avoid Doing This

2009-07-17T09:23:00.000-07:00

Summary:

Denial keeps us stuck in doing a negative event over and over again regardless of the outcome.
Be on guard for denial.
Denial rarely just goes away without being proactive and taking conscious action to intervene.
You must learn to deal with reality and get a better result!

Full-text here:
Want to Become a Winning Trader? Avoid Doing This…

PowerRatings Profit-Taking and Patience

2009-07-17T09:13:00.000-07:00

Summary:

As traders who buy the selling and sell the buying, we see the current strength in the stock market as an opportunity to ring the register, rather than to become over-eager about initiating new trades.
In fact, believe it or not, but PowerRatings traders are more likely to spend their time analyzing potential short candidates trading below their 200-day moving averages than they are to look for instances to chase runaway, overbought markets trading above their 200-day moving average.
But what moments like this really mean for PowerRatings traders – beyond taking profits in high PowerRatings stocks that were purchased on pullback – is patience.
These are the classic symptoms of overtrading and while overtrading can get any trader into trouble, overtrading is a particular bane of high probability traders – in large part because high probability requires patience in order to work Patience may not be fun, but it is a key to profits where high probability trading is concerned.

Full-text here: PowerRatings Profit-Taking and Patience

Earnings on a Good Day - $225.39 on CHK, GS, INTC, POT

2009-07-16T07:51:00.001-07:00

What I Bought When:
7/14/2009 BOUGHT 100 SHARES OF CHK AT $18.4398
7/14/2009 BOUGHT 20 SHARES OF GS AT $149.34
7/14/2009 BOUGHT 100 SHARES OF INTC AT $16.709
7/13/2009 BOUGHT 12 SHARES OF POT AT $83.27

What I Sold When:
7/15/2009 SOLD 100 SHARES OF CHK AT $19.1202
7/15/2009 SOLD 20 SHARES OF GS AT $151.71
7/15/2009 SOLD 100 SHARES OF INTC AT $18.031
7/15/2009 SOLD 12 SHARES OF POT AT $86.10

Total Profits:
68.04 CHK
33.96 POT
47.40 GS
132.20 INTC
------------
$281.6 - $56.21 (fees) =
$225.39 Total Profit from 2 days of trading.
Not bad for two days worth of risk taking. To be honest, this happened on giant overall jump in the stock market on July 14-15. A lot of people did good on these two days. Still, not bad. --kw

First Move for July 14 - Fast Money CNBC - One Day Returns

2009-07-14T18:42:00.000-07:00

First Move for July 14 - Fast Money CNBC - One Day Returns

How would you have fared if you had bought all of the Fast Money recommendations on July 14, 2009 for a one day return? Just curious. Here are the results:

ABT was up .74%
PDE was up 4.32%
V as down .1%
PKX was up 3.45% (but it was called as a short, not a long, so we will count this recommendation as a negative 3.45% because of earnings missed)
EXM was up 20.68

What is the average for all the recommendations on a one day return, just for the fun of it? Answer: Up 4.458% on average.

Average Gain of 4.124% in One Day on Jim Cramer's Stock Pics

2009-07-14T18:17:00.000-07:00

Average Gain of 4.124% in One Day on Jim Cramer's Stock Pics

If you are a swing or day trader, what if you had traded on Jim Cramer's recommendations on July 13. Here is what would have happened in one day. Of course, these results depend on many, many, many variables one of which is the trading climate. Check out these recommendations and their one day results:

AWI was up 2.93% in one day
OC was up 8.99% in one day
KALU was down 1.2% in one day
USG was up 5.56% in one day
GRA was up 4.34% in one day

An average gain of 4.124% in one day! Not bad for one day's work. Maybe we'll do this again here at Best Stocks to Trade. Check back in!

USU up 16.73% Since Tim Seymour's Recommendation on Fast Money CNBC - Rising Star Stock Pick

2009-07-14T10:40:00.000-07:00

USU up 16.73% Since Tim Seymour's Recommendation on Fast Money CNBC - Rising Star Stock Pick, July 14, 2009, 12:42 PM CT

"It’s the only American company in the space, explains Tim Seymour. And it has the backing of the US government. Also, valuations look cheap and from a technical perspective it’s behaving well." Full-text: http://www.cnbc.com/id/31893637

5 Small Companies Offering Big Stock Gains

2009-07-13T20:18:00.000-07:00

From www.SmartMoney.com
As a group, small-company stocks are providing just-OK returns this year. Those in the S&P SmallCap 600 index are up an average of 4.7%, vs. 4% for larger companies in the S&P 500 index.

But a handful of small companies are producing huge gains. That’s usually the case with small companies, since their returns tend to have what statisticians call a high standard deviation — a broad scattering — compared with large companies. Consider that 24 companies in the SmallCap 600 index have doubled their stock prices this year, compared with only five large companies in the 500 index. The top-gaining small company, retailer SteinMart (SMRT: 9.15, +0.17, +1.89%), is up nearly eightfold in price, while the winner among large companies, XL Capital (XL: 11.93, +0.88, +7.96%), has merely tripled.
Source: http://www.smartmoney.com/investing/stocks/5-small-companies-offering-big-stock-gains/

15 Stocks to Consider

2009-07-11T09:26:00.000-07:00

It is now four weeks since the S&P 500 [.SPX 879.13 -3.55 (-0.4%) ] hit its recent closing high of 946.21 on June 12. The benchmark index is down 6.7% since then and some components have been hit harder than others bringing dividend yields back up again. http://www.cnbc.com/id/31847725

The Latest Picks That Paid - Friday July 10th

2009-07-11T09:16:00.000-07:00

On June 23rd the Chairwoman suggested putting money where her mouth is. At the time she said, “I like Yum! [YUM 34.98 -0.02 (-0.06%) ] the owner of KFC, as well as Taco Bell and Pizza Hut. It’s a great way to play the growth of the middle class around the world.
http://www.cnbc.com/id/31850049

Web Extra: The Safe-Haven Trade

2009-07-11T09:10:00.000-07:00

The dollar [UUP] rose on Friday against a basket of currencies as investors rotated out of riskier assets and into the greenback as a safe haven.

What's the trade? http://www.cnbc.com/id/31850032

Your First Move For Monday July 13th

2009-07-11T09:04:00.000-07:00

Tim Seymour recommends long Potash [POT]
Guy Adami suggests long Dell [DEL]
Karen Finerman prefers long Flowserve [FLS]
Joe Terranova thinks Qualcomm [QCOM]
http://www.cnbc.com/id/31850066